UK Markets closed

BioNTech SE (BNTX)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
155.37-5.33 (-3.32%)
As of 02:16PM EST. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close160.70
Bid155.61 x 800
Ask156.04 x 800
Day's range152.88 - 164.35
52-week range90.29 - 464.00
Avg. volume3,514,932
Market cap37.68B
Beta (5Y monthly)-1.25
PE ratio (TTM)4.93
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Zacks

    Pfizer (PFE), BioNTech Begin Omicron-Based COVID-19 Jab Study

    Pfizer (PFE) and BioNTech (BNTX) announce that the first participants in a clinical study on its Omicron-specific COVID-19 vaccine candidate have been dosed.

  • Zacks

    Moderna (MRNA) Starts Study for Omicron-Specific Booster Jab

    Moderna (MRNA) doses the first participant in a phase II study on its Omicron specific COVID-19 booster candidate in a mid-stage study.

  • Motley Fool

    Why Coronavirus Vaccine Stocks Topped the Market Today

    Shares of coronavirus vaccine makers generally had a good Wednesday on the back of a coming push on additional jabs, plus a notable recommendation boost by a prominent investment bank. In contrast to the day's dip in the S&P 500 index, Moderna (NASDAQ: MRNA) stock enjoyed a 1.6% lift, Comirnaty vaccine co-developers Pfizer (NYSE: PFE) and BioNTech (NASDAQ: BNTX) respectively rose by 0.9% and 2.7%, and perennial underdog Novavax (NASDAQ: NVAX) gained 2.6%.